Knight Therapeutics Stock News

Knight Therapeutics Inc. (OTCPK:KHTRF) Q4 2022 Earnings Conference Call March 23, 2023 8:30 AM ET Company Participants Samira Sakhia - President, Chief Executive Officer Jeff Martens - Global Vice Pre

Knight Therapeutics Inc. (OTCPK:KHTRF) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Samira Sakhia - President and CEO Jeff Martens - Global VP of Commercial Arvin

Knight Therapeutics, Inc. (OTCPK:KHTRF) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Samira Sakhia - President & CEO Amal Khouri - CBO Arvind Utchanah - CFO Jeff Ma

MONTREAL, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2022 f

Knight Therapeutics Inc. (OTC:KHTRF) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Samira Sakhia - President and CEO Amal Khouri - Chief Business Officer Arvind Utchana

Knight Therapeutics Inc. ( TSX:GUD , Financial) is a specialty pharmaceutical company headquartered in Montreal, Canada and listed on the Toronto Stock Exchange. It's run by Jonathan Goodman, who buil

Knight Therapeutics Inc. (KHTRF) CEO Samira Sakhia on Q4 2021 Results - Earnings Call Transcript

Knight Therapeutics Inc. (TSE:GUD) Director Samira Sakhia bought 15,800 shares of the stock in a transaction on Monday, December 13th. The stock was acquired at an average price of C$5.20 per share, with a total value of C$82,160.00. Following the completion of the acquisition, the director now owns 83,786 shares of the companys stock, valued []

Knight Therapeutics Inc. (TSE:GUD) has been given a consensus rating of Buy by the six research firms that are covering the company, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have covered the stock in the last year is C$7.65. A number of []

Knight Therapeutics Inc. (TSE:GUD) Director Samira Sakhia acquired 15,800 shares of the businesss stock in a transaction dated Monday, December 13th. The shares were bought at an average cost of C$5.20 per share, for a total transaction of C$82,160.00. Following the transaction, the director now directly owns 83,786 shares in the company, valued at C$435,687.20. []

MONTREAL, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, is pleased to announce that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the upcoming Stifel GMP Future of Healthcare Conference on Wednesday, December 8, 2021 at 10 am ET, that will be held virtually. A live webcast of the event will be available at the following link: Event . A copy of the presentation will be available at www.gud-knight.com .

Shares of Knight Therapeutics Inc. (OTCMKTS:KHTRF) have received an average rating of “Buy” from the six research firms that are currently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have updated their coverage on the stock in the last […]

Raymond James set a C$8.50 price target on Knight Therapeutics (TSE:GUD) in a research report report published on Friday, BayStreet.CA reports. The brokerage currently has an outperform rating on the stock. Several other brokerages have also recently issued reports on GUD. National Bankshares increased their price target on shares of Knight Therapeutics from C$7.75 to […]

Raymond James set a C$8.50 target price on Knight Therapeutics (TSE:GUD) in a research note issued to investors on Friday, BayStreet.CA reports. The brokerage currently has an outperform rating on the stock. Several other analysts have also recently commented on GUD. Stifel Nicolaus upgraded Knight Therapeutics to a buy rating and set a C$6.50 price […]

Knight Therapeutics (TSE:GUD) has been given a C$8.50 price objective by equities researchers at Raymond James in a report issued on Friday, BayStreet.CA reports. The brokerage presently has an outperform rating on the stock. Raymond James price objective indicates a potential upside of 61.60% from the companys current price. A number of other equities analysts []